Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 4 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| T-Cell Surface Glycoprotein CD3 Epsilon Chain (T-Cell Surface Antigen T3/Leu-4 Epsilon Chain or CD3e) Overview | 7 | 1 |
| Therapeutics Development | 8 | 3 |
| T-Cell Surface Glycoprotein CD3 Epsilon Chain (T-Cell Surface Antigen T3/Leu-4 Epsilon Chain or CD3e) Products under Development by Stage of Development | 8 | 1 |
| T-Cell Surface Glycoprotein CD3 Epsilon Chain (T-Cell Surface Antigen T3/Leu-4 Epsilon Chain or CD3e) Products under Development by Therapy Area | 9 | 1 |
| T-Cell Surface Glycoprotein CD3 Epsilon Chain (T-Cell Surface Antigen T3/Leu-4 Epsilon Chain or CD3e) Products under Development by Indication | 10 | 1 |
| T-Cell Surface Glycoprotein CD3 Epsilon Chain (T-Cell Surface Antigen T3/Leu-4 Epsilon Chain or CD3e) Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| T-Cell Surface Glycoprotein CD3 Epsilon Chain (T-Cell Surface Antigen T3/Leu-4 Epsilon Chain or CD3e) Products under Development by Companies | 13 | 2 |
| T-Cell Surface Glycoprotein CD3 Epsilon Chain (T-Cell Surface Antigen T3/Leu-4 Epsilon Chain or CD3e) Products under Development by Universities/Institutes | 15 | 2 |
| T-Cell Surface Glycoprotein CD3 Epsilon Chain (T-Cell Surface Antigen T3/Leu-4 Epsilon Chain or CD3e) Therapeutics Assessment | 17 | 5 |
| Assessment by Monotherapy/Combination Products | 17 | 1 |
| Assessment by Mechanism of Action | 18 | 1 |
| Assessment by Route of Administration | 19 | 2 |
| Assessment by Molecule Type | 21 | 1 |
| T-Cell Surface Glycoprotein CD3 Epsilon Chain (T-Cell Surface Antigen T3/Leu-4 Epsilon Chain or CD3e) Companies Involved in Therapeutics Development | 22 | 5 |
| Amgen Inc. | 22 | 1 |
| GlaxoSmithKline Plc | 23 | 1 |
| MacroGenics, Inc. | 24 | 1 |
| Tiziana Life Sciences Plc | 25 | 1 |
| Xencor, Inc. | 26 | 1 |
| T-Cell Surface Glycoprotein CD3 Epsilon Chain (T-Cell Surface Antigen T3/Leu-4 Epsilon Chain or CD3e) Drug Profiles | 27 | 11 |
| foralumab Drug Profile | 27 | 1 |
| Monoclonal Antibodies to Activate CD3 and CD16 and to Inhibit HBsAg for HBV Infection and Oncology Drug Profile | 28 | 1 |
| otelixizumab Drug Profile | 29 | 2 |
| teplizumab Drug Profile | 31 | 2 |
| XENP-1138 Drug Profile | 33 | 1 |
| XmAb-13551 Drug Profile | 34 | 1 |
| XmAb-13677 Drug Profile | 35 | 2 |
| XmAb-14045 Drug Profile | 37 | 1 |
| T-Cell Surface Glycoprotein CD3 Epsilon Chain (T-Cell Surface Antigen T3/Leu-4 Epsilon Chain or CD3e) Dormant Projects | 38 | 1 |
| T-Cell Surface Glycoprotein CD3 Epsilon Chain (T-Cell Surface Antigen T3/Leu-4 Epsilon Chain or CD3e) Featured News &Press Releases | 39 | 13 |
| May 19, 2016: Immunotherapy Journal Review of Anti - CD3 Monoclonal Antibodies Highlights Therapeutic Potential of Tizianas Foralumab | 39 | 1 |
| Jan 11, 2016: Tiziana announces plans for clinical development of foralumab, the company fully human CD3 antibody | 39 | 1 |
| Nov 06, 2014: Xencor Provides Data Updates on XmAb Bispecific Antibody Programs and Announces Presentations at Upcoming American Society of Hematology 2014 Annual Meeting | 40 | 1 |
| Jun 28, 2011: MacroGenics Announces Publication Of Protege Phase III Clinical Data Of Teplizumab In The Lancet | 41 | 1 |
| Jun 23, 2011: MacroGenics To Present Protege Phase III Clinical Data Of Teplizumab In Type 1 Diabetes At ADA In San Diego, US | 42 | 1 |
| Mar 11, 2011: Tolerx And GSK Announce Phase III Defend-1 Study Of Otelixizumab In Type 1 Diabetes Fails Primary Endpoint | 42 | 1 |
| Oct 20, 2010: MacroGenics And Lilly Report Pivotal Clinical Trial Of Teplizumab Did Not Meet Primary Efficacy Endpoint | 43 | 1 |
| Sep 23, 2010: Tolerx Enrolls First Patient In Europe In DEFEND-2 Phase III Clinical Study For Treatment Of Type 1 Diabetes | 44 | 1 |
| Sep 23, 2010: Tolerx Presents Baseline Data From DEFEND-1 Study At European Association For Study Of Diabetes Annual Meeting | 45 | 1 |
| Jun 28, 2010: Tolerx Initiates Confirmatory Phase III Trial With Otelixizumab For Type 1 Diabetes | 46 | 1 |
| Jun 28, 2010: Tolerx Presents Baseline Data From DEFEND-1 Study Validating C-Peptide As Critical Clinical Measure For New-Onset Type 1 Diabetes | 46 | 1 |
| Mar 17, 2010: Single Short Course of Tolerx's Otelixizumab Provides Prolonged Preservation Of Beta Cell Function | 47 | 1 |
| Jan 07, 2010: Tolerx Completes Patient Enrollment For DEFEND-1 Phase 3 Clinical Study Of Otelixizumab, For The Treatment Of Type 1 Diabetes | 48 | 1 |
| Oct 21, 2009: Tolerx Presents Otelixizumab Phase II Dose Optimization Data At The IDF's 20TH World Diabetes Congress | 49 | 1 |
| Oct 21, 2009: Tolerx Presents Otelixizumab Phase II Dose Optimization Data At The IDF s 20TH World Diabetes Congress | 50 | 2 |
| Appendix | 52 | 2 |
| Methodology | 52 | 1 |
| Coverage | 52 | 1 |
| Secondary Research | 52 | 1 |
| Primary Research | 52 | 1 |
| Expert Panel Validation | 52 | 1 |
| Contact Us | 52 | 1 |
| Disclaimer | 53 | 1 |